FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer

WEDNESDAY, Oct. 23, 2024-- The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced...